文献速递急性肾损伤慢性肾脏病

ASSESS-AKI研究:尿表皮生长因子与主要不良肾脏事件风险降低相关

The ASSESS-AKI Study found urinary epidermal growth factor is associated with reduced risk of major adverse kidney events.
PubMed 文献 · Kidney Int · 2023-08-29

ASSESS-AKI多中心前瞻性观察队列纳入有或无AKI的住院患者,检测住院时和出院后3个月尿EGF/Cr,分析其与MAKE的关联。出院后3个月uEGF/Cr每升高2倍与MAKE风险降低独立相关(aHR 0.46),uEGF/Cr升高幅度最大者MAKE风险更低(aHR 0.52)。

要点

  • 出院后3个月uEGF/Cr每升高2倍,MAKE风险降低(aHR 0.46,95%CI 0.39-0.55)。
  • uEGF/Cr升高幅度最大者较变化最小者MAKE风险更低(aHR 0.52,95%CI 0.36-0.74)。
  • 3个月uEGF/Cr联合临床变量对MAKE区分度中等(AUC 0.73),对4年肾衰竭区分度强(AUC 0.96)。

核心结论

  • 尿EGF/Cr可能是远端小管健康的生物标志物,较高浓度及出院后uEGF/Cr升高与住院患者MAKE风险降低独立相关。

研究设计与样本

  • ASSESS-AKI研究为多中心、前瞻性、观察性队列,纳入有或无AKI的住院参与者,共1509例,随访4.3年。
  • 采用Cox比例风险回归分析住院时、出院后3个月uEGF/Cr及两时间点变化与MAKE的关联。
  • 机制研究比较小鼠缺血再灌注损伤后肾脏萎缩或修复模型中Egf相对表达。

主要发现

  • 1509例参与者中20%在4.3年随访期间发生MAKE。
  • 出院后3个月uEGF/Cr每升高2倍与MAKE风险降低相关(校正HR 0.46,95%CI 0.39-0.55)。
  • uEGF/Cr从住院到3个月升高幅度最大者较变化最小者MAKE风险更低(校正HR 0.52,95%CI 0.36-0.74)。
  • 3个月uEGF/Cr联合临床变量模型对MAKE区分度中等(AUC 0.73,95%CI 0.69-0.77),对4年肾衰竭区分度强(AUC 0.96,95%CI 0.92-1.00)。
  • 小鼠损伤后适应性修复模型中Egf表达恢复较进展性萎缩模型更快。

临床怎么用

  • 住院患者出院后3个月检测尿EGF/Cr可能有助于识别MAKE高风险个体。
  • uEGF/Cr联合临床变量可用于MAKE和肾衰竭的风险分层。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Biomarkers of tubular function such as epidermal growth factor (EGF) may improve prognostication of participants at highest risk for chronic kidney disease (CKD) after hospitalization. To examine this, we measured urinary EGF (uEGF) from samples collected in the Assessment, Serial Evaluation, and Subsequent Sequelae of Acute Kidney Injury (ASSESS-AKI) Study, a multi-center, prospective, observational cohort of hospitalized participants with and without AKI. Cox proportional hazards regression was used to investigate the association of uEGF/Cr at hospitalization, three months post-discharge, and the change between these time points with major adverse kidney events (MAKE): CKD incidence, progression, or development of kidney failure. Clinical findings were paired with mechanistic studies comparing relative Egf expression in mouse models of kidney atrophy or repair after ischemia-reperfusion injury. MAKE was observed in 20% of 1,509 participants over 4.3 years of follow-up. Each 2-fold higher level of uEGF/Cr at three months was associated with decreased risk of MAKE (adjusted hazards ratio 0.46, 95% confidence interval: 0.39-0.55). Participants with the highest increase in uEGF/Cr from hospitalization to three-month follow-up had a lower risk of MAKE (adjusted hazards ratio 0.52; 95% confidence interval: 0.36-0.74) compared to those with the least change in uEGF/Cr. A model using uEGF/Cr at three months combined with clinical variables yielded moderate discrimination for MAKE (area under the curve 0.73; 95% confidence interval: 0.69-0.77) and strong discrimination for kidney failure at four years (area under the curve 0.96; 95% confidence interval: 0.92-1.00). Accelerated restoration of Egf expression in mice was seen in the model of adaptive repair after injury, compared to a model of progressive atrophy. Thus, urinary EGF/Cr may be a biomarker of distal tubular health, with higher concentrations and increased uEGF/Cr post-discharge independently associated with reduced risk of MAKE in hospitalized patients.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Menez S, Wen Y, Xu L, et al. The ASSESS-AKI Study found urinary epidermal growth factor is associated with reduced risk of major adverse kidney events. Kidney Int. 2023. PMID: 37652206. doi:10.1016/j.kint.2023.08.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。